Sustained efficacy and safety of burosumab, a fully human anti-FGF23 monoclonal antibody, in children and early adolescents with X-linked hypophosphatemia
Hogler W, Carpenter T, Imel E, Portale A, Boot A, Linglart A, Padidela R, Hoff W, Mao M, Skrinar A, Martin J, Whyte M. Sustained efficacy and safety of burosumab, a fully human anti-FGF23 monoclonal antibody, in children and early adolescents with X-linked hypophosphatemia. Bone Abstracts 2019 DOI: 10.1530/boneabs.7.oc15.Peer-Reviewed Original Research